UCM Stock Overview
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.06|
|52 Week High||AU$0.15|
|52 Week Low||AU$0.056|
|1 Month Change||-14.29%|
|3 Month Change||-40.00%|
|1 Year Change||-58.62%|
|3 Year Change||-53.85%|
|5 Year Change||-67.57%|
|Change since IPO||-97.50%|
Recent News & Updates
|UCM||AU Medical Equipment||AU Market|
Return vs Industry: UCM underperformed the Australian Medical Equipment industry which returned -17.2% over the past year.
Return vs Market: UCM underperformed the Australian Market which returned -7.9% over the past year.
|UCM Average Weekly Movement||8.8%|
|Medical Equipment Industry Average Movement||11.5%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.5%|
|10% least volatile stocks in AU Market||4.7%|
Stable Share Price: UCM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: UCM's weekly volatility (9%) has been stable over the past year.
About the Company
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company provides the SpiroSonic AIR, a digital home care spirometer which feeds digital lung function signals through a phone app; and Ventitest, a digital ultrasonic ventilator testing solution for testing ventilators.
Uscom Fundamentals Summary
|UCM fundamental statistics|
Is UCM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UCM income statement (TTM)|
|Cost of Revenue||AU$215.69k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.008|
|Net Profit Margin||-46.70%|
How did UCM perform over the long term?See historical performance and comparison
Is UCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UCM?
Other financial metrics that can be useful for relative valuation.
|What is UCM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does UCM's PS Ratio compare to its peers?
|UCM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
AMT Allegra Orthopaedics
CBL Control Bionics
EYE Nova Eye Medical
RHT Resonance Health
Price-To-Sales vs Peers: UCM is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (4.6x).
Price to Earnings Ratio vs Industry
How does UCM's PE Ratio compare vs other companies in the AU Medical Equipment Industry?
Price-To-Sales vs Industry: UCM is good value based on its Price-To-Sales Ratio (3.5x) compared to the Australian Medical Equipment industry average (6.6x)
Price to Sales Ratio vs Fair Ratio
What is UCM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.5x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate UCM's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of UCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UCM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UCM's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Uscom forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uscom has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Uscom performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UCM is currently unprofitable.
Growing Profit Margin: UCM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UCM is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare UCM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).
Return on Equity
High ROE: UCM has a negative Return on Equity (-23.98%), as it is currently unprofitable.
Discover strong past performing companies
How is Uscom's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: UCM's short term assets (A$7.1M) exceed its short term liabilities (A$946.5K).
Long Term Liabilities: UCM's short term assets (A$7.1M) exceed its long term liabilities (A$1.3M).
Debt to Equity History and Analysis
Debt Level: UCM is debt free.
Reducing Debt: UCM has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UCM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: UCM has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 25.2% each year.
Discover healthy companies
What is Uscom current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UCM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as UCM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Rob Phillips (69 yo)
Dr. Robert Allan Phillips, also known as Rob, Ph D.(Med), MPhil (Med), FASE, DMU, AMS, FIR, is the Founder of Uscom Limited and serves as its Chief Scientist. Dr. Phillips has been the Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD472.82K) is above average for companies of similar size in the Australian market ($USD280.13K).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
Experienced Board: UCM's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.5%.
Uscom Limited's employee growth, exchange listings and data sources
- Name: Uscom Limited
- Ticker: UCM
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$11.918m
- Shares outstanding: 198.64m
- Website: https://www.uscom.com.au
Number of Employees
- Uscom Limited
- 66 Clarence Street
- Suite 2
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.